Compared to rodents and non-human primates, large animal models such as dogs and miniature pigs offer unique advantages. They provide a balance between genetic, physiological, and structural similarities to humans, while maintaining relatively low experimental costs, making them invaluable in research and medical applications.
These models are particularly effective in studying cardiovascular, neurological, dermatological, inflammatory immune, and endocrine/metabolic diseases.
For instance, the Medicilon Large Animal Pharmacodynamic Research Service Platform supports a wide array of disease models, including but not limited to:
1. Metabolic diseases: obesity, diabetes, and hyperuricemia.
2. Cardiovascular diseases: thrombosis, stroke, and atherosclerosis.
3. Inflammatory and immune diseases: arthritis, osteoporosis, and psoriasis.
This broad range of applications addresses nearly all major disease areas relevant to current drug development.
Large animal models can simulate the pharmacokinetic and pharmacodynamic characteristics of the human body, enabling researchers to better understand drug absorption, distribution, metabolism, and excretion processes. They are also ideal for safety assessments, offering effective evaluations of organ and system-level effects.
At Medicilon, we go beyond standard disease model development. We specialize in creating customized complex disease models tailored to clients' unique needs. From drug screening and efficacy evaluation to safety assessments, our Large Animal Pharmacodynamic Research Service Platform provides end-to-end services designed to accelerate the drug development process.
Share：
marketing@medicilon.com
